- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03508713
Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND) (LELAND)
Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND): a Multicenter Prospective Observational Study in Southern China
To focus on the real world treat-to-target rate of early rheumatoid arthritis patients who will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA.
To explore the factors which influence the treat-to-target outcome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Resent study showed that rapid progression of cartilage and bone damage could happen on the early state of RA patients, so the clinicians should try the best to stop the trend, such as early diagnosis, early treatment and treat-to-target. But only half of the RA patients could reach low disease activity in the whole world and about 10% in China.
The investigators enroll early RA patients who are treated according to the 2015 American College of Rheumatology Guideline. The relevant data are collected and analyzed by the statistician including clinical data, imaging markers, blood samples and patient-reported outcomes every 3 months.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Min Yang, doctor
- Phone Number: +86-13802911770
- Email: minyanggz@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥18 years,
- be diagnosed with RA according to the 1987 or 2010 ACR criteria,
- in the course of the disease within 6 months,
- fill out questionnaires by oneself,
- fully understand the survey, agree to take part in the survey with signing the informed consent, and authority the researchers to expose and use his or her personal health information.
Exclusion Criteria:
- woman in pregnancy, lactation or plan to pregnant in the next 2 years,
- before enter this study, the patient joint any other RA clinical study in the past 24 weeks,
- according to the clinicians, one may not report his /or her life quality or the utilization of leading medical resources.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
early RA patients
patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months.
If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.
|
Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of patients achieving treat to target
Time Frame: 2018-4-25 to 2022-7-1
|
calculate the proportion of patients achieving treat to target according to the change of DAS28 score
|
2018-4-25 to 2022-7-1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change of Health Assessment Questionnaire Disability Index(HAQ-DI)
Time Frame: 2018-4-25 to 2022-7-1
|
the change of Health Assessment Questionnaire Disability Index(HAQ-DI)
|
2018-4-25 to 2022-7-1
|
the change of The Work Productivity and Activity Impairment Questionnaire(WPAI)
Time Frame: 2018-4-25 to 2022-7-1
|
the change of The Work Productivity and Activity Impairment Questionnaire(WPAI)
|
2018-4-25 to 2022-7-1
|
the change of European Quality of Life-5 Dimensions(EQ-5D)
Time Frame: 2018-4-25 to 2022-7-1
|
the change of European Quality of Life-5 Dimensions(EQ-5D)
|
2018-4-25 to 2022-7-1
|
the change of Short Form 36 Health Survey Questionnaire(SF-36)
Time Frame: 2018-4-25 to 2022-7-1
|
the change of Short Form 36 Health Survey Questionnaire(SF-36)
|
2018-4-25 to 2022-7-1
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Min Yang, doctor, Nanfang Hospital of Southern Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LC2016PY020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on disease modified antirheumatic drugs or biological agents
-
Universidade Nova de LisboaCentro Hospitalar de Vila Nova de Gaia/Espinho; Centro Hospitalar Lisboa Ocidental... and other collaboratorsRecruitingArthritis, Rheumatoid | Axial SpondyloarthritisPortugal
-
Uppsala UniversityCompletedSpinal Fractures | Ankylosing Spondylitis
-
University Health Network, TorontoPancreatic Cancer CanadaActive, not recruitingResectable Pancreatic CancerCanada
-
University of PennsylvaniaAdaptimmuneCompletedHIV InfectionsUnited States
-
Hematology department of the 920th hospitalRecruitingSevere Aplastic AnemiaChina
-
University of ZurichUniversity Hospital, Zürich; Center of Competence Multimorbidity, ZurichCompletedDiabetes Complications | Gastrointestinal Hemorrhage | MultimorbiditySwitzerland
-
Fundación Santa Fe de BogotaUnknownCovid19 | Rheumatic Diseases
-
University of AthensUnknownInflammation | Rheumatoid ArthritisGreece
-
University Hospital, Clermont-FerrandRecruitingHereditary Hemorrhagic Telangiectasia | Rendu Osler DiseaseFrance
-
University of British ColumbiaUniversity of Manitoba; Alberta Health services; University of Alberta; Dalhousie... and other collaboratorsCompletedMultiple Sclerosis